We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Unicycive Therapeutics Inc (UNCY) USD0.001

Sell:$0.44 Buy:$0.45 Change: $0.0316 (7.20%)
Market closed |  Prices as at close on 18 July 2024 | Switch to live prices |
Change: $0.0316 (7.20%)
Market closed |  Prices as at close on 18 July 2024 | Switch to live prices |
Change: $0.0316 (7.20%)
Market closed |  Prices as at close on 18 July 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Unicycive Therapeutics, Inc. is a biotechnology company that is developing treatments for certain medical conditions. Its programs are focused on kidney disease, an area that has the potential to offer medical benefits. Its development programs are focused on two novel therapies: Oxylanthanum Carbonate, and UNI 494. Oxylanthanum Carbonate is a novel investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. UNI-494 is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury. Oxylanthanum Carbonate and UNI 494 were initially developed by and licensed to it from Spectrum Pharmaceuticals (Spectrum) and Sphaera Pharma, respectively.

Contact details

4300 El Camino Real, Suite 210
United States
+1 (650) 3840642

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$17.75 million
Shares in issue:
37.61 million
United States
US dollar

Key personnel

  • Shalabh Gupta
    Chairman of the Board, President, Chief Executive Officer, Founder
  • John Townsend
    Chief Financial Officer
  • Pramod Gupta
    Executive Vice President - Pharmaceutical and Business Operations
  • Doug Jermasek
    Executive Vice President, Corporate Strategy

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.